VISIT US IN CHICAGO JUNE 2-4 AT BOOTH 2073!

Dr. Jonasch on Promise of Immuno-Oncology Agents in RCC

Eric Jonasch, MD
Published: Saturday, Feb 18, 2017



Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.

Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.
 


Eric Jonasch, MD, professor, The University of Texas MD Anderson Cancer Center, discusses the promise of immuno-oncology agents in sarcomatoid renal cell carinoma (RCC).

Sarcomatoid RCC is a difficult disease in regard to efficacy, says Jonasch. But, with studies stating that PD-L1 expression in RCC is high, the use of checkpoint antibodies could be promising.

Jonasch says that this high expression of PD-L1 supports the hypothesis that, if targeted, checkpoint antibodies could be succesful in treatment of patients with the disease.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
34th Annual Miami Breast Cancer Conference® Clinical Case Vignette Series™May 25, 20182.0
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Publication Bottom Border
Border Publication
x